Despite the initial enthusiasm with this phase II study, to our knowledge, there are no active clinical trials studying eprenetapopt as post-alloHSCT maintenance in TP53-mutated MDS or AML. This evidence concerns the gene TP53 and myelodysplastic syndrome.